Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
37.01
-1.33 (-3.47%)
At close: Aug 25, 2025, 4:00 PM
37.25
+0.24 (0.65%)
After-hours: Aug 25, 2025, 5:35 PM EDT
Cytokinetics Stock Forecast
Stock Price Forecast
The 12 analysts that cover Cytokinetics stock have a consensus rating of "Buy" and an average price target of $71.58, which forecasts a 93.41% increase in the stock price over the next year. The lowest target is $41 and the highest is $120.
Price Target: $71.58 (+93.41%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Cytokinetics stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 4 | 4 | 4 |
| Buy | 9 | 10 | 7 | 7 | 7 | 7 |
| Hold | 2 | 2 | 3 | 3 | 3 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 17 | 18 | 16 | 14 | 14 | 13 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $80 → $77 | Strong Buy | Maintains | $80 → $77 | +108.05% | Aug 8, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $71 → $53 | Buy | Maintains | $71 → $53 | +43.20% | Jun 9, 2025 |
| Mizuho | Mizuho | Buy Maintains $103 → $84 | Buy | Maintains | $103 → $84 | +126.97% | May 29, 2025 |
| Needham | Needham | Strong Buy Reiterates $72 | Strong Buy | Reiterates | $72 | +94.54% | May 14, 2025 |
| Barclays | Barclays | Buy Maintains $55 → $53 | Buy | Maintains | $55 → $53 | +43.20% | May 8, 2025 |
Financial Forecast
Revenue This Year
79.62M
from 18.47M
Increased by 330.96%
Revenue Next Year
138.06M
from 79.62M
Increased by 73.41%
EPS This Year
-5.69
from -5.26
EPS Next Year
-5.89
from -5.69
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 124.3M | 245.7M | 509.0M | ||
| Avg | 79.6M | 138.1M | 352.5M | ||
| Low | 1.6M | 49.0M | 213.5M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 572.7% | 208.6% | 268.7% | ||
| Avg | 331.0% | 73.4% | 155.3% | ||
| Low | -91.5% | -38.5% | 54.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -5.37 | -4.29 | -0.54 | ||
| Avg | -5.69 | -5.89 | -3.95 | ||
| Low | -6.19 | -7.07 | -5.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.